MSB Trading 2021 - paradigm shift, page-7834

“So they're developing potency assays. That's good, that's what the FDA wants.

But what I'm saying is we haven't had any word of progress or how they intend to overcome the innate difficulties involved in assays for MSCs - this is the issue.

Throwing ten million at the problem is great. But it's a problem money may not be able to solve, and we've been in the dark with regards to details for over a year.”

Let me think for a minute. What you are proposing is that they let the world know in detail how they are addressing the concerns of the FDA. Seems reasonable to me, not! There are numerous stem cell companies that would love to know how to solve potency issues in the future. Well, we may as well hand it to them on a plate, gift wrapped in pretty ribbons.

C’mon you can do better than that surely?